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Sir,
Enterocutaneous fistula (ECF)-related morbidity and mortality can be high due
to fluid loss and electrolyte imbalance, sepsis, and malnutrition. ECF is a rare
problem in hemodialysis (HD) patients. Even in non-renal patients with ECF,
disagreement about therapeutic options remains. To the best of our knowledge,
we report the first clinical experience among HD patients related to the treatment
of postoperative ECF by somatostatin.
31-year-old female HD patient was admitted to our emergency department with
complaints of abdominal pain, weakness, and lack of appetite that had developed
during the 16 hours since the last HD session. Primary kidney disease was focal
segmental glomerulosclerosis which was diagnosed in 1997. She has been treated
by HD, three times a week for three years. 
Diffuse intraabdominal bleeding and multiple hematomas were considered as
diagnosis. Laparatomy was performed and diagnosis was confirmed. This
problem may have resulted from prolonged bleeding of left ovarian corpus
haemorrhagicum due to administration of classical heparin.
Three weeks after operation, purulent incisional drainage and fever developed.
Despite empirical antimicrobial treatment, fever and drainage continued to
increase. On the 3
rd day, drainage composition included intestinal fluid. ECF was
considered and confirmed by abdominal CT. Inflammatory bowel disease (i.e.
Crohn’s disease) was eliminated. Oral intake was stopped and total parenteral
nutrition (TPN) was started. Despite ten days of TPN and parenteral antibiotic
treatment, the amount of drainage gradually increased to 425 mL/day. At that
point, TPN and antibiotics were stopped, and somatostatin was administered
alone for ten days (250 µg, intravenous [i.v.] bolus; then, 250 µg/day, i.v. for 10
days). On the 4
th day of treatment, drainage decreased gradually and ECF closure
defined as no fistula output for 2 successive days was achieved completely on the
9
th day of treatment. The patient was discharged as healthy, and was followed
asymptomatically for three months.
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A postoperative ECF is a very rare problem in HD
patients. There are a few medical treatment options for
ECFs, including TPN, high dose i.v. immunoglobulin,
somatostatin and its analogue octreotide. In fact, these
options were developed and reported in the literature
primarily for the non-renal population. Their efficacies in
HD patients are still unclear. 
Pharmacological treatment of patients with ECFs aims
at reducing output, increasing the chance of spontaneous
closure and reducing the time until fistula closure. Soma-
tostatin inhibits several gastrointestinal functions. In cases
where total TPN alone for 7 days has failed to influence
high output fistulas, overall data support the use of adju-
vant drug, somatostatin, or its synthetic analogue, octreotide,
in non-renal patients (1). Somatostatin is potent in inhibition
of glucagon release, splanchnic blood flow, intestinal
motility and gastric exocrine secretion. Somatostatin 250
µg/d and its analogue, octreotide 300-600 µg/d have been
employed along with TPN to decrease the healing time of
ECFs and to reduce the number of complications.
1 While
some authors suggested that various kinds of ECF; includ-
ing postoperative, intestinal, pancreatic, biliary, malignant
or multiple ECF were treated successfully by somatostatin
or octreotide,
1 other authors disagreed.
2 Spiliotis et al.
3
showed that somatostatin is superior to TPN alone for ECF
treatment. 
The plasma somatostatin levels increase due to reduced
clearance in HD patients, and renal insufficiency may,
itself, induce an increase in some gastrointestinal peptides
capable of stimulating somatostatin secretion.
4 HD treat-
ment does not produce any changes in somatostatin levels.
5
As such, we did not change our patient’s dialysis schedule.
Because it is rarely used, the adverse effects spectrum of
somatostatin remains unknown in HD patients. Some
authors noted that somatostatin treatment may result in
hyperkalemia in HD patients.
6 Under these circumstances,
our patient showed no clinical or laboratory adverse effect
during treatment and after.  
To the best of our knowledge, this is the first clinical
experience with somatostatin among HD patients with
ECF. We concluded that somatostatin has been shown to
be very useful in the conservative treatment of ECFs in
HD patients without serious adverse effect, because of its
ability to rapidly reduce fistula output and accelerate spon-
taneous closure. 
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